Clinical Trials
3 trialsNCT06435312 2026-05-08
ziMyG+
UCB Pharma
Phase 3 Enrolling by invitation
NCT06540144 2026-05-08
An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Enrolling by invitation
NCT05374590 2026-04-23
ADAPT Jr +
argenx
Phase 2/3 Enrolling by invitation